Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meifeng Tu

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|April 5, 2017
PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphomaWen Zheng, Hanyun Ren, Xiaoyan Ke, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 11, 2017
NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53Qingqing Cai, Meifeng Tu, Zijun Y Xu-Monette, et al.
Molecular Therapy Oncolytics|October 26, 2019
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's LymphomaZhitao Ying, Ting He, Xiaopei Wang, et al.
BMC Cancer|September 23, 2018
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivityWen Zheng, Yuhuan Gao, Xiaoyan Ke, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|March 31, 2022
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphomaZhitao Ying, Ting He, Shanzhao Jin, et al.
Cancer Medicine|April 14, 2020
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decadesWeiping Liu, Xinqiang Ji, Yuqin Song, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 21, 2016
[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]Weiping Liu, Xiaopei Wang, Chen Zhang, et al.
Cancer Cell International|March 1, 2019
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphomaYalu Liu, Xiaogan Wang, Lijuan Deng, et al.
Bone Marrow Transplantation|December 8, 2022
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trialZhitao Ying, Yan Xie, Wen Zheng, et al.
Oncotarget|August 29, 2015
Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven originLijuan Deng, Yuqin Song, Ken H Young, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|April 5, 2017
PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphomaWen Zheng, Hanyun Ren, Xiaoyan Ke, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 11, 2017
NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53Qingqing Cai, Meifeng Tu, Zijun Y Xu-Monette, et al.
Molecular Therapy Oncolytics|October 26, 2019
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's LymphomaZhitao Ying, Ting He, Xiaopei Wang, et al.
BMC Cancer|September 23, 2018
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivityWen Zheng, Yuhuan Gao, Xiaoyan Ke, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|March 31, 2022
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphomaZhitao Ying, Ting He, Shanzhao Jin, et al.
Cancer Medicine|April 14, 2020
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decadesWeiping Liu, Xinqiang Ji, Yuqin Song, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 21, 2016
[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]Weiping Liu, Xiaopei Wang, Chen Zhang, et al.
Cancer Cell International|March 1, 2019
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphomaYalu Liu, Xiaogan Wang, Lijuan Deng, et al.
Bone Marrow Transplantation|December 8, 2022
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trialZhitao Ying, Yan Xie, Wen Zheng, et al.
Oncotarget|August 29, 2015
Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven originLijuan Deng, Yuqin Song, Ken H Young, et al.
Pageof 4